Aurobindo gets FDA approval for generic Tambocor

DAYTON, N.J. — Aurobindo announced recently that the Food and Drug Administration had approved its generic version of Tambocor (flecainide acetate tablets) in 50-, 100- and 150-mg dosage strengths.

The drug is meant to prevent paroxysmal supraventricular tachycardias (PSVT), as well as prevention and treatment of certain severe ventricular-related arrhythmias. In the 12 months that ended April 2015, Tambocor brought in $67.3 million in sales, according to IMS Health.

This is the 144th ANDA approval for Aurobindo, and the company has 120 applications pending before the FDA.